NCT03030248 2026-04-15
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Medical College of Wisconsin
Phase 2 Completed
Clinical Trials
12 trialsNCT07220967 2026-04-09
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
Memorial Sloan Kettering Cancer Center
Phase 4 Recruiting
NCT04983901 2026-04-06
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04948463 2026-03-20
ELSA-FN
Murdoch Childrens Research Institute
Phase 4 Completed
NCT07478848 2026-03-18
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 1 Not yet recruiting
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03546829 2026-01-14
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT04729322 2025-12-23
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06126731 2025-11-24
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT04208958 2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2 Completed
NCT06540391 2025-09-26
MELODY-1
Microbiotica Ltd
Phase 1 Active not recruiting
NCT05690048 2025-08-06
FLORA
University Hospital Heidelberg
Phase 2 Recruiting